Result:Very GoodBroad basedMargin expansionRecord quarter
| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 178.86 Cr | 31.1% | 35.6% |
| Total Income | 181.48 Cr | 31.4% | 29.1% |
| Expenditure | 151.44 Cr | 25.3% | 18.3% |
| PBT | 30.04 Cr | 51.2% | 138.2% |
| Net Profit | 22.97 Cr | 51.6% | 139.3% |
| OPM | 19.12% | 5.33pp | 11.46pp |
| NPM | 12.66% | 5.30pp | 5.83pp |
| EPS | 17.18 | 51.6% | 139.3% |
Pharma core revenue grew a strong 35.6% YoY while OPM expanded sharply from 7.7% to 19.1%, driving PAT up 139% with no signs of one-off gains.
Informational and educational content only. Not investment advice.